Abstract
1.AbstractBackground & AimCo-amoxiclav is a commonly used antibiotic. Although, the dose administered during renal replacement therapy may be subtherapeutic. This study aims to describe the current literature on the pharmacokinetics and pharmacodynamics of co-amoxiclav in patientss undergoing renal replacement therapy.MethodWe carried out a systematic review of the available literature in MEDLINE, Embase, Pubmed, and Google Scholar from inception to Oct 2023. Studies were included if they reported pharmacokinetic data on adults given amoxicillin or clavulanic acid during renal replacement therapy.ResultsSeven studies were identified which were published between 1984 to 2021. Variability was observed in the participant characteristics within the studies, the renal replacement therapy settings, the drug exposure, drug assay methods, and the analysis of the pharmacokinetic parameters.ConclusionFurther pharmacokinetic-pharmacodynamic studies are needed on co-amoxiclav during renal replacement therapy.
Publisher
Cold Spring Harbor Laboratory
Reference21 articles.
1. Co-amoxiclav Specific Product Characteristics. [cited 29.01.2023]. Available at: https://www.medicines.org.uk/emc/product/7211/smpc#gref
2. British National Formula. [cited 29.01.2023]. Available at: https://bnf.nice.org.uk/
3. Ashley C , Dunleavy A . The renal drug database. [accessed: 27/1/2024] Available at: https://renaldrugdatabase.com
4. EUCAST. European Committee on antimicrobial susceptibility testing. [cited 11/5/21]. Available from: www.eucast.org
5. Early acute kidney injury and sepsis: a multicentre evaluation